virus
caus
larg
number
diseas
human
fatal
other
highli
debilit
major
viral
diseas
attack
infant
young
children
other
strike
peopl
prime
develop
prevent
measur
viral
diseas
therefor
paramount
import
vaccin
costeffect
medic
intervent
prevent
mortal
morbid
infecti
diseas
number
effect
safe
vaccin
current
avail
sever
viral
diseas
signific
medic
import
mani
manufactur
india
par
intern
standard
afford
mani
viral
diseas
vaccin
current
avail
research
underway
variou
nation
laboratori
well
privat
sector
compani
india
present
overview
highlight
variou
vaccin
prevent
viral
diseas
special
import
india
aim
provid
glimps
variou
vaccin
current
avail
develop
india
india
strong
presenc
global
vaccin
scenario
current
least
major
vaccin
manufactur
countri
number
steadili
increas
india
major
import
well
export
vaccin
indian
market
vaccin
valu
usd
vaccin
one
power
costeffect
health
intervent
invent
vaccin
provid
benefit
level
individu
also
societi
larg
power
prevent
primari
diseas
also
complic
sequela
mani
medic
import
viral
diseas
preval
india
vaccin
two
name
polio
measl
find
place
univers
immun
programm
uip
implement
govern
india
diseas
find
place
uip
bacteri
origin
name
diphtheria
pertussi
tetanu
childhood
tuberculosi
uip
vaccin
avail
free
cost
uip
one
largest
program
kind
world
term
number
vaccin
dose
use
number
peopl
reach
undoubtedli
multipl
issu
hinder
introduct
vaccin
nation
programm
spite
avail
vaccin
one
major
hindranc
cost
other
includ
programmat
logist
issu
well
absenc
diseaseburden
data
certain
case
mani
viral
diseas
total
erad
imposs
due
zoonot
natur
diseas
like
polio
measl
stori
differ
two
childhood
viral
diseas
total
erad
sinc
human
be
host
requir
concert
sustain
global
effort
activ
public
particip
cooper
case
smallpox
erad
planet
earth
million
india
major
supplier
vaccin
unit
nation
children
fund
unicef
meet
global
vaccin
demand
routin
childhood
immun
program
approxim
develop
countri
develop
biolog
vaccin
goe
handinhand
endeavor
develop
drug
diagnost
india
abl
contribut
allround
develop
health
sector
sinc
excel
r
infrastructur
public
well
privat
sector
sinc
independ
establish
topclass
research
institut
medic
colleg
hospit
excel
drug
test
laboratori
biosafeti
lab
clinic
trial
center
clinic
research
organ
cro
worldclass
facil
major
r
facil
public
sector
includ
indian
immunolog
ltd
bharat
immunolog
biolog
corp
ltd
haffkin
biopharmaceut
corp
ltd
central
research
institut
kasauli
counterpart
privat
sector
includ
serum
institut
india
ltd
bharat
biotech
intern
ltd
shantha
biotech
panacea
biotec
ltd
new
vaccin
product
plant
complet
dholka
gujarat
cpl
biolog
joint
ventur
cadila
pharmaceut
ltd
novavax
inc
usa
plant
capac
manufactur
million
dose
season
pandem
flu
vaccin
annual
punebas
serum
institut
india
make
one
everi
two
vaccin
produc
world
interestingli
serum
institut
india
first
indian
compani
approach
world
health
organ
develop
manufactur
pandem
influenza
vaccin
institut
launch
intranas
vaccin
nasovac
tm
juli
panacea
biotec
new
delhi
play
major
role
polio
erad
programm
suppli
billion
dose
oral
polio
vaccin
opv
govern
india
unicef
south
shantha
biotech
shanvacb
first
indian
hepat
b
vaccin
prequalifi
global
distribut
un
agenc
shantha
hepat
b
vaccin
price
onetenth
import
vaccin
along
five
indian
compani
enter
market
india
cheapest
hepat
b
vaccin
world
moreov
recent
effort
govern
india
central
research
institut
kasauli
pasteur
institut
india
coonoor
bcg
vaccin
laboratori
guindi
enabl
resum
vaccin
product
henc
inde
excit
time
vaccin
product
india
present
overview
aim
highlight
major
viral
diseas
vaccin
either
avail
india
clinic
preclin
develop
countri
provid
bird
eye
view
epidemiolog
clinic
featur
current
diagnost
treatment
modal
well
prevent
measur
special
stress
vaccin
tabl
provid
key
detail
viral
vaccin
produc
india
arbovir
arthropodborn
viral
diseas
constitut
major
categori
viral
diseas
transmit
arthropod
eg
mosquito
sandfli
tick
import
accord
group
viral
diseas
stem
fact
india
significantli
high
densiti
mosquito
popul
wide
distribut
variou
mosquito
speci
global
arbovirus
known
caus
human
diseas
signific
presenc
india
arbovirus
public
health
import
belong
one
three
viru
genus
flaviviru
alphaviru
bunyaviru
indian
context
japanes
enceph
viru
jev
dengu
viru
denv
two
import
flavivirus
wherea
chikungunya
viru
chikv
import
alphaviru
although
epidemiolog
diseas
uniqu
certain
degre
similar
underli
diseas
particularli
refer
socioeconom
ecolog
environment
factor
substanti
contribut
emerg
spread
susten
diseas
natur
japanes
enceph
viru
jev
lead
caus
brain
fever
children
jev
flaviviru
spread
human
anim
culicin
mosquito
virion
particl
spheric
nm
diamet
envelop
possess
singlestrand
positivesens
nonseg
rna
genom
approxim
kb
length
genom
code
viral
protein
vp
three
structur
capsid
premembran
membran
envelop
seven
nonstructur
viru
respons
caus
japanes
enceph
je
import
form
viral
enceph
global
je
origin
japan
late
sinc
spread
vast
region
south
southeast
asia
approxim
billion
peopl
risk
contract
je
needless
say
je
major
public
health
problem
region
account
case
fatal
conserv
figur
may
mere
indic
proverbi
tipoftheiceberg
india
je
first
report
vellor
formerli
north
arcot
district
tamil
nadu
total
case
report
area
first
major
outbreak
occur
burdwan
bankura
district
west
bengal
case
death
year
je
epidem
report
part
india
becom
endem
sever
district
comprehens
figur
je
diseas
burden
india
constitut
substanti
proport
total
global
burden
jev
maintain
natur
mean
zoonot
cycl
involv
culicin
mosquito
vector
pig
amplifi
host
ardeid
bird
vertebr
reservoir
human
act
call
deadend
host
sinc
infect
jev
usual
produc
suffici
high
titer
viremia
propag
viru
je
zoonosi
total
erad
effect
kept
check
prophylact
vaccin
suscept
human
popul
vaccin
becom
import
control
je
sinc
current
effect
treatment
avail
coupl
fact
vector
control
measur
total
effect
mous
brainderiv
formalininactiv
je
vaccin
produc
central
research
institut
kasauli
till
coupl
year
ago
vaccin
larg
effect
although
concern
relat
safeti
besid
vaccin
produc
limit
quantiti
price
high
vaccin
product
facil
centuryold
central
research
institut
kasauli
compli
intern
accept
cgmp
guidelin
je
vaccin
product
halt
howev
coupl
je
vaccin
advanc
stage
develop
front
runner
ixiaro
purifi
inactiv
vaccin
piv
develop
intercel
austria
imojev
chimer
vaccin
sanofi
pasteur
employ
yellow
fever
viru
chimerivax
technolog
platform
two
vaccin
proven
exemplari
throughout
preclin
clinic
develop
refer
safeti
efficaci
two
cardin
properti
good
vaccin
intercel
indian
partner
biolog
e
manufactur
market
ixiaro
india
indian
govern
current
import
sa
primari
hamster
kidney
phk
cellcultur
liveattenu
je
vaccin
chengdu
institut
biolog
product
china
vaccin
safe
efficaci
also
cheap
taken
intern
commun
due
phk
cell
substrat
use
prepar
interest
see
govern
adopt
chang
je
vaccin
polici
ixiaro
becom
avail
indian
market
import
factor
affect
decisionmak
process
definit
cost
intercel
vaccin
like
much
costlier
chines
vaccin
howev
unlik
hindranc
ixiaro
commerci
viabil
intercel
primari
target
tourism
market
sinc
tourist
west
increasingli
prefer
travel
exot
destin
inevit
je
endem
henc
effort
develop
safe
effect
indigen
je
vaccin
like
cheaper
still
continu
laboratori
nation
institut
immunolog
engag
endeavor
past
sever
year
util
convent
vaccin
develop
strategi
cell
cultur
viru
follow
formalininactiv
well
newer
approach
involv
recombin
dna
techniqu
piv
develop
use
indian
strain
jev
grown
vero
cell
technolog
transfer
panacea
biotec
commerci
develop
jev
dna
vaccin
candid
evalu
nonhuman
primat
limit
success
adenoviru
vector
jev
vaccin
candid
shown
promis
result
mice
due
widespread
presenc
neutral
antibodi
human
popul
recent
disappoint
outcom
base
hiv
vaccin
trial
effort
use
novel
adenovir
vector
engin
recombin
je
vaccin
denv
flaviviru
transmit
human
aed
mosquito
virion
structur
genom
organ
similar
jev
viru
respons
dengu
fever
denf
lifethreaten
complic
name
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
diseas
caus
four
relat
antigen
distinct
denv
denv
billion
peopl
risk
contract
dengu
million
individu
infect
annual
undoubtedli
seriou
global
public
health
problem
denv
transmit
primarili
aed
aegypti
although
aed
albopictu
also
implic
denv
danger
arbovirus
transmissiondynam
standpoint
viremia
human
suffici
high
propag
viru
henc
unlik
jev
infect
human
act
deadendhost
case
denv
infect
vertebr
reservoiramplifi
host
requir
mainten
viru
natur
exampl
urban
set
denv
lifecycl
easili
maintain
human
mosquito
major
risk
factor
occurr
dengu
complic
exist
subneutr
level
circul
antibodi
heterolog
denv
strain
may
acquir
utero
mosquito
bite
give
rise
antibodi
depend
enhanc
ade
believ
phenomenon
ade
aris
subneutr
antibodi
becom
complex
heterotyp
denv
secondari
infect
result
taken
effici
fc
receptorbear
monocyt
macrophag
tackl
complic
den
dhf
dss
medic
emerg
requir
immedi
hospit
order
save
patient
often
schoolgo
children
current
specif
antivir
treatment
den
manag
complic
support
involv
fluid
replac
order
counteract
plasma
leakag
observ
grade
iiiiv
dhf
dss
moreov
even
implement
support
care
hinder
absenc
lowcost
rapid
diagnost
test
rdt
suffici
high
specif
sensit
accur
predict
diseas
sever
den
prevent
vaccin
suscept
human
popul
effort
direct
global
three
decad
albeit
without
much
success
indian
effort
develop
dengu
vaccin
intern
center
genet
engin
biotechnolog
icgeb
util
adenovirusvector
approach
develop
tetraval
denv
vaccin
candid
gene
encod
domain
iii
envelop
e
protein
ediii
respect
denv
strain
stitch
togeth
creat
tetraval
gene
ediiit
cassett
insert
replicationdefect
vector
vaccin
candid
evalu
mice
cellmedi
immun
respons
well
virusneutr
antibodi
gener
vaccin
construct
suffer
limit
vector
describ
effort
current
ongo
icgeb
produc
ediiit
pichia
express
system
chikv
alphaviru
spread
human
aed
mosquito
alphavirus
small
envelop
virus
nm
diamet
possess
singlestrand
positivesens
rna
genom
approxim
kb
length
genom
organ
two
distinct
region
twothird
encod
nonstructur
protein
nsp
onethird
encod
four
major
structur
protein
includ
capsid
protein
three
envelop
protein
chikungunya
fever
chikf
clinic
character
triad
symptom
includ
fever
rash
arthralgia
clinic
diagnosi
chikf
complic
fact
mani
clinic
featur
overlap
denf
henc
effort
need
direct
toward
develop
chikvspecif
diagnost
use
field
situat
especi
epidem
chikf
specif
treatment
treatment
pure
symptomat
support
commerci
chik
vaccin
current
avail
anywher
world
although
effort
develop
tissu
cultur
deriv
viruslik
particl
vlp
base
vaccin
follow
recent
reemerg
viru
mani
part
asia
includ
explos
outbreak
india
amount
stagger
million
case
effort
also
india
develop
vero
cell
cultur
inactiv
chikv
vaccin
scientist
defenc
research
develop
establish
drde
gwalior
develop
vero
cell
adapt
formalininactiv
chikv
vaccin
candid
use
indian
strain
chikv
drde
isol
patient
hyderabad
outbreak
immun
swiss
albino
mice
inactiv
vaccin
gener
high
titer
chikv
neutral
antibodi
howev
efficaci
vaccin
formul
test
mean
vitro
vivo
neutral
test
direct
challeng
experi
anim
model
lethalclin
dose
viru
carri
chpv
rhabdoviru
nonseg
singlestrand
negativesens
rna
genom
rhabdovirus
deriv
name
greek
word
rhabdo
mean
rodshap
virus
exhibit
typic
bulletshap
morpholog
common
member
rabi
viru
discuss
later
chpv
virion
consist
ribonucleoprotein
rnp
particl
core
contain
nonseg
singlestrand
genom
rna
wrap
around
nucleocapsid
protein
n
viral
rna
depend
rna
polymeras
rdrp
compos
larg
protein
l
catalyt
subunit
phosphoryl
form
phosphoprotein
p
act
transcript
activ
compon
viral
rdrp
l
p
packag
within
matur
virion
remain
associ
core
rnp
particl
matur
viru
cover
outer
lipoprotein
envelop
e
glycoprotein
g
protrud
extern
outer
membran
matrix
protein
lie
within
bilay
structur
membran
g
spike
protein
chpv
enabl
virion
adsorpt
assembl
bud
help
tether
core
rnp
particl
membran
chpv
first
isol
two
adult
patient
suffer
febril
ill
villag
call
chandipura
nagpur
region
maharashtra
henc
name
chandipura
viru
chpv
subsequ
isol
child
suffer
acut
enceph
raipur
chhattisgarh
although
epidem
potenti
viru
initi
underestim
chpv
outbreak
two
consecut
year
andhra
pradesh
gujarat
follow
anoth
nagpur
divis
highlight
chpv
emerg
pathogen
demand
due
share
attent
arboviru
commun
chpv
spread
sandfli
phlebotomu
argentip
demonstr
viru
isol
vector
aurangabad
well
detect
viral
rna
karimnagar
recent
suscept
transmiss
potenti
phlebotomu
argentip
chpv
conclus
demonstr
experiment
laboratori
condit
main
clinic
featur
chpv
enceph
chpe
includ
fever
seizur
alter
sensorium
headach
often
accompani
gi
tract
symptom
shock
rash
hemorrhag
symptom
present
less
often
major
complic
enceph
specif
treatment
chpe
mainstay
support
hospitalbas
care
coupl
good
nurs
chpe
held
check
prophylact
vaccin
suscept
popul
along
vector
control
measur
current
chpe
vaccin
avail
commerci
candid
chpv
vaccin
develop
india
nation
institut
virolog
vaccin
candid
base
glycoprotein
g
gene
chpv
express
recombin
protein
use
baculoviru
express
system
immunogen
studi
mice
shown
promis
result
particularli
fact
intracerebr
ic
challeng
use
homolog
chpv
led
protect
besid
arbovir
diseas
quit
viral
diseas
india
essenti
endem
pose
major
public
health
problem
mani
vaccin
prevent
diseas
vpd
also
major
global
problem
particularli
develop
countri
brief
overview
vpd
special
concern
india
given
india
diarrheal
diseas
respons
approxim
death
infant
children
year
age
amount
estim
death
annual
rotaviru
rv
respons
substanti
proport
death
estim
annual
hospit
million
outpati
visit
annual
year
age
rv
belong
famili
reovirida
classifi
seven
group
ag
group
b
c
known
infect
human
group
rv
lead
caus
diarrhea
infant
children
group
b
c
primarili
respons
sporad
case
rv
nonenvelop
doublestrand
rna
virus
segment
genom
divid
segment
segment
genom
allow
extens
recombin
among
variou
strain
result
tremend
divers
rv
strain
genom
segment
code
vp
nsp
viral
capsid
enclos
rna
genom
compos
three
vp
name
bear
antigen
determin
respons
group
subgroup
specif
pproteasesensit
gglycoprotein
determin
pand
gtype
variou
rv
strain
form
basi
classif
variou
serotyp
around
gand
pgenotyp
g
p
report
common
strain
infect
children
worldwid
p
p
p
rv
diseas
character
wateri
diarrhea
often
accompani
fever
vomit
nausea
lead
rapid
dehydr
fatal
absenc
medic
intervent
specif
treatment
rv
infect
main
aim
therapi
maintain
electrolyt
balanc
revers
dehydr
administ
oral
rehydr
solut
or
howev
cost
incur
manag
rv
diseas
quit
stagger
sumtot
direct
medic
direct
nonmed
cost
born
indian
public
health
system
tackl
rv
diarrhea
case
annual
approxim
usd
million
coupl
diseas
burden
make
compel
case
introduc
prophylact
measur
vaccin
two
us
fdaapprov
rv
vaccin
rotateq
merck
sharp
dohm
rotarix
glaxosmithklin
current
avail
intern
rotateq
pentaval
live
oral
vaccin
made
humanbovin
reassort
rv
contain
rotarix
monoval
live
oral
vaccin
made
human
rv
strain
howev
vaccin
expens
indian
context
feasibl
incorpor
indian
childhood
immun
program
would
much
depend
costeffect
avail
effort
also
develop
cheaper
indigen
rv
vaccin
one
rv
vaccin
candid
base
strain
genotyp
p
origin
isol
neonat
india
institut
medic
scienc
aiim
new
delhi
recent
complet
doseescal
random
doubleblind
placebocontrol
trial
infant
new
delhi
studi
indic
vaccin
candid
elicit
robust
immun
respons
follow
three
dose
phase
iii
clinic
trial
vaccin
candid
current
progress
indigen
vaccin
candid
success
effect
yet
cheaper
altern
alreadi
licens
rv
vaccin
anoth
candid
base
uk
humanbovin
reassort
develop
nation
institut
health
nih
bethesda
usa
licens
serum
institut
india
pune
shantha
biotech
hyderabad
develop
rabi
one
oldest
zoonot
viral
diseas
plagu
india
sinc
vedic
time
span
well
year
although
rabi
viru
rabv
born
larg
number
terrestri
well
fli
mammal
dog
still
major
reservoir
viru
india
estim
death
occur
annual
due
rabi
india
account
approxim
global
death
annual
incid
rabi
india
per
popul
two
distinct
clinic
syndrom
recogn
humansfuri
encephalit
paralyt
furiou
form
character
fever
distal
paresthesia
fascicul
alter
sensorium
pleocytosi
cerebrospin
fluid
accompani
rapid
progress
symptom
compar
easier
diagnos
paralyt
form
pose
difficulti
diagnosi
exhibit
similar
symptom
syndrom
absenc
histori
dog
bite
clinic
pictur
similar
psychiatr
syndrom
incub
period
rabv
unlik
viral
infect
quit
long
rang
week
year
typic
month
howev
note
symptom
diseas
develop
rabi
fatal
anim
human
moreov
sinc
specif
test
rabv
current
avail
absenc
classic
rabiesspecif
sign
hydrophobia
aerophobia
clinic
diagnosi
difficult
rabv
belong
famili
rhabdovirida
virion
helic
symmetri
nm
length
nm
diamet
envelop
virus
singlestrand
negativesens
rna
genom
genet
inform
tightli
packag
rnp
complex
genom
encod
nucleoprotein
n
phosphoprotein
p
matrix
protein
glycoprotein
g
rdrp
l
rabi
effect
prevent
vaccin
vaccin
given
preexposur
well
postexposur
preexposur
prophylaxi
recommend
anyon
increas
risk
exposur
rabv
laboratori
worker
postexposur
prophylaxi
recommend
affect
individu
essenti
two
type
vaccin
human
use
nerv
tissu
vaccin
ntv
cell
cultur
vaccin
ccv
ntv
produc
grow
rabv
sheep
brain
india
call
sempl
vaccin
british
director
central
research
institut
kasauli
develop
techniqu
turn
last
centuri
sempl
vaccin
requir
larg
number
pain
intramuscular
im
inject
moreov
sinc
contain
myelin
protein
possibl
occurr
allerg
encephalomyel
aem
certain
vaccin
recipi
recommend
ntv
replac
efficaci
safer
ccv
follow
suprem
court
order
product
sempl
vaccin
ban
gradual
phase
indian
health
system
two
approv
ccv
avail
india
two
decad
includ
purifi
chick
embryo
cell
pcec
vaccin
rabipur
produc
chiron
vaccin
india
market
sanofi
aventi
india
purifi
vero
cell
rabi
vaccin
pvrv
manufactur
sanofi
pasteur
franc
market
ranbaxi
india
brand
name
verorab
consid
high
price
vaccin
rabi
ccv
develop
indigen
indirab
tm
vero
cellbas
rabi
vaccin
manufactur
bharat
biotech
intern
ltd
hyderabad
found
safe
immunogen
human
abhayrab
tm
anoth
pvrv
avail
indian
immunolog
ltd
hyderabad
rabi
vaccin
also
prepar
use
human
diploid
cell
intern
standard
merieux
inactiv
rabi
vaccin
mirv
manufactur
sanofi
pasteur
lyon
franc
serum
institut
india
pune
indigen
develop
adsorb
human
diploid
cell
rabi
vaccin
rabivax
use
pitmanmoor
rabv
strain
grown
human
diploid
cell
follow
inactiv
bpl
vaccin
found
immunogen
safe
rabi
prophylaxi
human
purifi
duck
embryo
vaccin
pdev
rabi
manufactur
berna
biotech
switzerland
avail
intern
lyssavac
n
two
decad
follow
technolog
transfer
vaccin
manufactur
india
zydu
cadila
health
care
ltd
ahmedabad
market
vaxirab
open
label
random
phase
iv
compar
clinic
trial
indic
vaxirab
safe
toler
immunogen
rabipur
verorab
two
approv
vaccin
could
use
altern
vaccin
postexposur
prophylaxi
rabi
multicentr
studi
also
indic
safeti
efficaci
indigen
manufactur
pdev
postexposur
prophylaxi
purpos
immunotherapi
antirabv
immunoglobulin
rais
hors
also
avail
indian
market
exampl
abhayrig
avail
indian
immunolog
ltd
hyderabad
equirab
avail
bharat
serum
vaccin
ltd
thane
vaccin
deliveri
standpoint
establish
intraderm
id
rout
much
costeffect
convent
im
rout
amount
reduct
cost
besid
vaccin
discuss
far
alreadi
avail
indian
market
least
two
indigen
antirabi
dna
vaccin
candid
current
develop
moreov
microparticlebas
deliveri
system
also
explor
india
evid
multiprong
approach
requir
reduc
human
rabi
case
india
strategi
need
adopt
includ
compulsori
licens
vaccin
pet
dog
ii
stringent
dog
birth
control
programm
control
popul
stray
street
dog
iii
issu
incorpor
preexposur
rabi
vaccin
childhood
immun
programm
need
consid
iv
sustain
inform
educ
commun
iec
activ
v
declar
rabi
notifi
diseas
henc
prevent
human
rabi
longrun
requir
allinclus
coordin
communitybas
effort
activ
particip
gener
public
nongovernment
organ
ngo
well
govern
staff
veterinari
public
health
wing
health
system
hepat
b
global
public
health
problem
approxim
billion
peopl
ie
almost
third
world
popul
infect
viru
least
million
death
occur
annual
relat
hepat
b
viru
hbv
infect
india
intermedi
endem
hepat
b
surfac
antigen
hbsag
preval
million
hbsag
carrier
india
death
annual
india
account
global
death
due
hbv
infect
hbv
dna
viru
belong
famili
hepadnavirida
virion
particl
envelop
lipid
cover
enclos
nucleocapsid
core
turn
enclos
viral
dna
dna
polymeras
hbv
replic
hepatocyt
human
higher
primat
hbsag
lipoprotein
viral
envelop
neutral
epitop
larg
bodi
evid
suggest
major
infant
eantigen
posit
hbsag
carrier
mother
much
like
becom
chronic
infect
unless
vaccin
birth
thu
mothertochild
transmiss
time
birth
common
mode
transmiss
hbv
amongst
adult
peopl
high
risk
hbv
infect
includ
patient
sexual
transmit
infect
sti
homosexu
promiscu
heterosexu
commerci
sex
worker
injectiondrug
user
household
contact
chronic
infect
hbv
patient
chronic
renal
failur
patient
requir
regular
hemodialysi
patient
requir
blood
product
hiv
patient
healthcar
worker
hbv
exposur
occup
hazard
number
strategi
primarili
base
vaccin
need
adopt
block
transmiss
hbv
includ
univers
vaccin
birth
ii
compulsori
screen
pregnant
women
hbsag
iii
postexposur
immunotherapi
infant
born
hbsag
women
iv
catchup
vaccin
children
adolesc
v
vaccin
atrisk
adult
case
hbv
hbsag
protect
antigen
current
hepat
b
vaccin
contain
hbsag
produc
recombin
dna
technolog
avail
monoval
formul
fixeddos
combin
vaccin
vaccin
use
combo
includ
diphtheriatetanuspertussi
dtp
haemophilu
influenza
type
b
hib
hepat
inactiv
polio
vaccin
ipv
immunogen
safeti
profil
combo
compar
vaccin
administ
individu
howev
immun
birth
monoval
hbv
vaccin
recommend
administ
within
h
birth
particular
requir
steep
challeng
hepat
b
vaccin
india
birth
still
take
place
home
often
remot
inaccess
povertystricken
area
reach
newborn
within
short
time
period
major
hindranc
introduc
vaccin
uip
recombin
hepat
b
vaccin
current
manufactur
indigen
number
lead
indian
compani
includ
serum
institut
india
shantha
biotech
panacea
biotec
other
thu
avail
vaccin
suitabl
price
suppli
public
health
system
problem
requir
outofthebox
think
troubleshoot
programmat
issu
order
expedit
hepat
b
vaccin
programm
alreadi
commenc
projectmod
sinc
design
citi
india
human
papilloma
viru
hpv
belong
famili
papovavirida
nonenvelop
virion
particl
nm
diamet
doubl
strand
dna
genet
materi
hpv
epitheliotrop
viru
human
caus
prolif
lesion
epiderm
mucos
epithelia
type
hpv
identifi
least
type
infect
genit
mucosa
human
henc
sexual
transmit
hpv
type
categor
lowand
highrisk
type
former
respons
genit
wart
well
recurr
respiratori
papillomatosi
rrp
latter
respons
cervic
cancer
common
lowrisk
hpv
type
caus
genit
wart
common
highrisk
hpv
type
account
cervic
cancer
hpv
infect
one
common
sti
amongst
women
approxim
sexual
activ
women
men
becom
infect
hpv
point
live
infect
transient
usual
clear
immun
respons
usual
present
clinic
symptom
howev
persist
infect
lead
cervic
cancer
india
estim
new
case
cervic
cancer
death
annual
current
two
licens
vaccin
gardasil
merck
sharp
dohm
cervarix
gsk
avail
intern
vlpbase
vaccin
former
quadrival
cover
hpv
type
latter
bival
cover
hpv
type
although
indian
academi
pediatr
committe
immun
iapcoi
recommend
hpv
vaccin
femal
children
age
year
age
afford
vaccin
access
vaccin
moment
restrict
econom
welloff
class
iron
requir
vaccin
least
access
lifesav
vaccin
hinder
exorbit
cost
expens
vaccin
produc
far
retail
price
india
complet
schedul
gardasil
rs
cervarix
rs
clearli
indic
vaccin
still
essenti
outofreach
gener
indian
public
henc
strong
argument
develop
indigen
hpv
vaccin
would
afford
henc
access
develop
hpv
vaccin
indigen
price
competit
greater
access
target
popul
technic
econom
feasibl
retrospect
may
rememb
hbv
vaccin
introduc
earli
price
usd
per
dose
one
costliest
vaccin
time
howev
within
decad
compani
develop
countri
like
india
develop
introduc
vaccin
usd
per
dose
due
ensu
competit
came
less
cent
per
dose
approach
feasibl
hpv
vaccin
four
lead
indian
compani
name
shantha
biotech
serum
institut
india
bharat
biotech
indian
immunolog
current
develop
hpv
vaccin
could
much
cheaper
current
vaccin
shantha
even
indic
vaccin
could
initi
price
usd
besid
compani
two
other
name
virchow
biotech
gennova
biopharmaceut
also
develop
hpv
vaccin
support
depart
biotechnolog
dbt
govern
india
biotechnolog
industri
partnership
programm
bipp
effort
still
infanc
go
time
indian
hpv
vaccin
becom
avail
measl
acut
viral
ill
infant
children
major
public
health
problem
develop
countri
like
india
one
singlemost
import
caus
childhood
mortal
prodrom
stage
diseas
exhibit
nonspecif
symptom
viral
infect
character
fever
malais
conjunct
respiratori
symptom
coryza
cough
characterist
clinic
featur
measl
appear
rash
erythemat
maculopapular
natur
begin
head
spread
trunk
final
limb
span
day
two
day
onset
rash
koplik
spot
pathognomon
enanthem
measl
appear
mucosa
buccal
caviti
diseas
highli
contagi
spread
droplet
transmiss
common
complic
measl
otiti
media
pneumonia
diarrhea
convuls
rare
complic
includ
enceph
subacut
scleros
panenceph
sspe
measl
viru
mv
member
famili
paramyxovirida
kb
singlestrand
rna
neg
polar
genom
genom
encod
six
protein
structur
protein
three
protein
nucleoprotein
n
phosphoprotein
p
larg
protein
l
complex
viral
rna
form
nucleocapsid
three
protein
matrix
protein
hemagglutinin
h
fusion
protein
f
particip
format
viral
envelop
measl
vpd
incorpor
uip
commerci
liveattenu
measl
vaccin
avail
serum
institut
india
mvac
tm
use
edmonstonzagreb
strain
mv
propag
human
diploid
cell
spite
avail
cheap
measl
vaccin
india
measl
vaccin
programm
face
mani
problem
challeng
includ
unfinish
polio
erad
agenda
lack
surveil
vpd
well
financi
manpow
constraint
tradit
low
routin
immun
coverag
india
estim
million
infant
miss
first
dose
measl
vaccin
routin
immun
servic
million
india
alon
account
global
figur
india
countri
world
introduc
second
dose
measl
vaccin
spite
document
evid
efficaci
two
dose
vaccin
reduc
measl
relat
mortal
moreov
india
follow
recommend
made
strateg
advisori
group
expert
sage
immun
novemb
administ
two
dose
measl
vaccin
recent
time
death
four
infant
shortli
administr
measl
vaccin
possibl
due
human
error
led
public
distrust
vaccin
effort
urgent
need
initi
seconddos
measl
vaccin
india
well
catchup
vaccin
children
yet
receiv
first
dose
measl
vaccin
mump
viru
also
member
famili
paramyxovirida
mump
spread
droplet
infect
mainli
affect
schoolgo
children
mump
also
known
parot
clinic
character
swell
pain
parotid
salivari
gland
orchiti
occur
one
four
male
develop
mump
puberti
oophor
correspond
symptom
adolesc
femal
incub
period
day
mump
also
vpd
vaccin
avail
india
rubella
viru
envelop
rna
viru
sole
member
genu
rubiviru
famili
togavirida
rubella
also
known
german
measl
also
vpd
transmit
droplet
infect
diseas
tend
affect
older
children
adolesc
young
adult
spread
less
readili
measl
clinic
cours
diseas
gener
mild
complet
recoveri
rule
diseas
particular
relev
occur
pregnant
women
within
first
month
pregnanc
caus
congenit
abnorm
fetu
women
receiv
prior
vaccin
rubella
serum
institut
india
manufactur
liveattenu
rubella
vaccin
rvac
tm
prepar
propag
wistar
ra
rubella
viru
strain
human
diploid
cell
combin
measlesmumpsrubella
mmr
vaccin
provid
protect
mump
addit
measl
rubella
also
manufactur
serum
institut
india
tresivac
tm
liveattenu
lzagreb
strain
mump
viru
propag
chick
embryo
fibroblast
cell
use
combin
vaccin
prepar
mmr
vaccin
avail
indian
immunolog
abhayvac
manufactur
viru
strain
exactli
fashion
serum
institut
vaccin
mmr
vaccin
exhibit
seroconvers
measl
rubella
seroconvers
mump
infant
month
age
moreov
immun
gener
longlast
signific
level
seroposit
even
year
post
vaccin
indian
academi
pediatr
iap
recommend
two
dose
mmr
vaccin
one
month
age
year
age
due
sever
complic
aris
measl
adult
recent
outbreak
mump
includ
india
well
rubella
seroposit
infant
suspect
infect
utero
well
pregnant
women
recommend
advisori
committe
immun
practic
acip
adult
born
receiv
least
two
dose
mmr
vaccin
unless
otherwis
contraind
effort
direct
vaccin
suscept
adolesc
adult
especi
rubella
particularli
women
child
bear
age
sinc
viru
caus
congenit
defect
contract
pregnanc
acut
respiratori
infect
ari
major
killer
children
develop
countri
respons
million
death
annual
death
occur
india
alon
influenza
frequent
caus
ari
requir
medic
attent
affect
age
group
recurr
influenza
viru
infv
belong
famili
orthomyxovirida
envelop
virion
segment
negativestrand
rna
genom
influenza
virus
classifi
three
genera
name
b
c
first
two
known
caus
human
diseas
infv
type
basi
two
surfac
proteinshemagglutinin
ha
neuraminidas
na
influenza
b
virus
possess
eight
differ
rna
segment
code
differ
protein
respect
influenza
c
virus
lack
na
gene
thu
seven
rna
code
least
nine
differ
polypeptid
india
season
influenza
case
influenc
climat
fluctuat
although
defin
season
pattern
gener
observ
northern
india
case
occur
winter
south
case
occur
monsoon
season
viral
ari
india
caus
primarili
influenza
b
virus
parainfluenza
viru
respiratori
syncyti
viru
rsv
burden
season
influenza
india
appear
low
although
crosssect
studi
well
activ
surveil
requir
howev
influenza
account
larg
number
absente
school
colleg
offic
annual
believ
current
suffici
reason
initi
vaccin
season
influenza
india
season
influenza
prevent
implement
simpl
public
health
intervent
hand
wash
soap
inculc
habit
improv
gener
respiratori
hygien
howev
surveil
system
place
vaccin
option
may
kept
open
special
case
mass
human
congreg
occur
religi
occas
like
mahakumbh
mela
ganga
sagar
mela
muslim
pilgrimag
hajj
kept
mind
influenza
virus
mutat
rapidli
antigen
shift
oppos
slower
chang
antigen
drift
occur
longer
period
time
moreov
gene
infv
differ
speci
recombin
undergo
reassort
give
rise
infv
pandem
potenti
influenza
viru
caus
influenza
swine
flu
pandem
viru
also
jump
speci
barrier
occur
avian
influenza
outbreak
birdspecif
influenza
viru
infect
human
bird
flu
viru
origin
china
rapidli
spread
across
three
continentsasia
africa
europ
caus
outbreak
countri
includ
india
threat
like
bird
flu
real
check
implement
surveil
system
close
monitor
virus
circul
bird
especi
direct
bear
human
poultri
realli
justif
develop
bird
flu
vaccin
due
limit
humantohuman
transmiss
potenti
moreov
human
case
treat
antivir
oseltamivir
amantadin
outbreak
poultri
control
effect
cull
activ
howev
pandem
influenza
viru
vaccin
essenti
current
india
swine
flu
vaccin
manufactur
serum
institut
india
pune
liveattenu
vaccin
nasovac
tm
use
california
isol
human
propag
specif
pathogen
free
spf
embryon
hen
egg
follow
lyophil
formul
intranas
administr
serum
institut
india
also
develop
immunogen
monoclon
antibodi
pandem
fund
dbt
bipp
moreov
panacea
biotec
also
develop
pandem
influenza
vaccin
fund
sourc
bharat
biotech
also
pandem
influenza
vaccin
product
pipelin
opinion
pandem
influenza
swine
flu
vaccin
reserv
individu
highrisk
contract
infect
manag
outbreak
situat
poliomyel
commonli
refer
polio
ageold
viral
diseas
affect
human
sinc
time
immemori
fact
egyptian
stone
carv
suggest
polio
could
exist
sinc
prebibl
time
far
back
bc
polio
acut
ill
follow
invas
gastrointestin
gi
tract
one
three
serotyp
polio
viru
polio
virus
enterovirus
belong
famili
picornavirida
sinc
small
pico
possess
rna
genom
indic
wild
polio
virus
wpv
three
viru
replic
gut
invad
bloodstream
high
degre
tropism
nervou
tissu
peripher
nerv
becom
infect
viru
reach
central
nervou
system
cn
retrograd
axon
transport
infect
might
clinic
asymptomat
symptom
appear
may
rang
fever
asept
mening
paralysi
infect
spread
fecoor
rout
well
pharyng
secret
infect
individu
overcrowd
poor
sanit
facilit
rapid
spread
polio
major
reason
diseas
endem
develop
countri
polio
vpd
vaccin
diseas
develop
half
centuri
ago
ipv
develop
jona
salk
liveattenu
opv
develop
albert
sabin
vaccin
effort
essenti
erad
diseas
western
hemispher
global
polio
erad
initi
gpei
publicpriv
partnership
establish
led
nation
govern
spearhead
cdc
unicef
rotari
intern
drive
forc
behind
effort
direct
global
polio
erad
larg
due
huge
global
effort
polio
verg
erad
current
four
countri
afghanistan
india
nigeria
pakistan
polio
endem
four
other
africa
reestablish
polio
transmiss
countri
report
import
polioviru
case
due
sustain
vaccin
effort
erad
wild
last
case
detect
india
final
stage
erad
process
goal
wipe
remain
type
circul
endem
area
highli
infecti
caus
paralysi
widespread
local
northern
india
northern
nigeria
pakistan
afghanistan
order
tackl
problem
bival
opv
bopv
develop
random
doubleblind
control
trial
indic
superior
bopv
compar
trival
opv
topv
noninferior
compar
monoval
monoval
bopv
first
introduc
afghanistan
decemb
million
children
year
old
receiv
vaccin
vaccin
introduc
india
januari
follow
polio
case
decreas
dramat
april
histor
poliopron
state
uttar
pradesh
report
singl
case
polio
year
last
case
report
april
ferozabad
singl
paralyticpolio
case
report
far
year
infect
report
januari
howrah
district
west
bengal
set
west
bengal
outbreak
respons
team
action
initi
subnat
immun
day
snid
sinc
april
effort
check
polio
case
fact
india
current
fare
better
countri
exampl
democrat
republ
congo
case
pakistan
case
chad
case
report
compar
much
higher
number
polio
case
far
year
india
current
manufactur
type
opv
contribut
immens
polio
erad
programm
suppli
vaccin
intern
organ
like
unicef
panacea
biotec
india
lead
manufactur
polio
vaccin
manufactur
entir
discontinu
topv
phase
bopv
haffkin
biopharmaceut
corpor
ltd
hbpcl
manufactur
topv
phase
bopv
bharat
biotech
manufactur
topv
biopolio
tm
phase
needless
say
opv
intern
qualiti
except
bharat
biotech
topv
prequalifi
vaccin
seem
stage
set
polio
erad
globe
howev
extens
surveil
requir
gather
evid
wpv
might
circul
environ
well
vaccineassoci
paralyt
polio
vapp
case
appear
emerg
problema
byproduct
intens
polio
vaccin
campaign
year
acquir
immun
defici
syndrom
aid
pandem
caus
human
immunodefici
viru
hiv
ravag
globe
nearli
three
decad
still
show
sign
abat
current
million
peopl
live
hivaid
worldwid
becom
infect
everi
day
undoubtedli
one
greatest
human
calam
caus
viru
modern
time
hiv
belong
famili
retrovirida
virion
possess
enzym
call
revers
transcriptas
rt
enzym
caus
revers
transcript
viral
genet
inform
contain
rna
genom
dna
uniqu
sens
goe
gener
flow
genet
inform
dna
rna
protein
per
central
dogma
two
type
caus
human
diseas
respons
global
aid
pandem
also
caus
aid
progress
much
slower
essenti
limit
countri
west
africa
portug
discoveri
hiv
earli
earli
optim
indic
vaccin
would
soon
develop
howev
initi
optim
dampen
continu
setback
face
year
major
obstacl
includ
vast
genet
variabl
hiv
aris
absenc
proofread
mechan
rt
allow
mutat
happen
rapidli
replic
cycl
absenc
suitabl
anim
model
also
major
hindranc
vaccin
develop
effort
chimpanze
model
far
ideal
moreov
clear
correl
protect
necessit
phase
iii
human
clinic
trial
order
establish
efficaci
vaccin
three
separ
largescal
phase
iii
clinic
trial
vax
vax
rv
conduct
total
human
volunt
yet
vaccin
candid
unabl
prevent
infect
intern
aid
vaccin
initi
iavi
found
global
notforprofit
publicpriv
partnership
work
acceler
develop
hivaid
vaccin
iavi
current
support
five
clinic
trial
candid
aid
vaccin
two
trial
intermitt
preexposur
prophylaxi
prep
regimen
collabor
indian
council
medic
research
icmr
iavi
support
phase
clinic
trial
evalu
safeti
immunogen
primeboost
regimen
two
aid
vaccin
candid
advax
initi
analys
data
gather
trial
suggest
vaccin
regimen
safe
immunogen
spite
suboptim
result
clinic
trial
gener
new
knowledg
help
design
develop
new
vaccin
candid
fact
recent
model
studi
indic
hivaid
vaccin
possess
efficaci
could
develop
administ
popul
would
reduc
annual
number
new
infect
howev
three
decad
sustain
global
effort
wide
accept
develop
hivaid
vaccin
one
difficult
challeng
confront
biomed
scientist
today
quest
goe
viral
diseas
major
impact
health
indian
burgeon
popul
zoonot
previous
undisturb
increasingli
encroach
human
consequ
mani
viral
diseas
previous
unheardof
emerg
quiescent
decad
reemerg
vaccin
could
confer
protect
mani
emerg
viral
diseas
howev
sever
key
programmat
area
need
look
properli
address
order
ensur
vaccin
becom
realiti
one
area
requir
attent
improv
understand
diseas
burden
surveil
establish
integr
surveil
system
across
asia
variou
stakehold
countri
contribut
susten
need
hour
help
detect
diseas
like
sever
acut
respiratori
syndrom
sar
caus
larg
outbreak
india
lucki
last
time
one
import
case
sar
next
time
luck
might
india
side
sinc
improv
aviat
send
infect
peopl
part
globe
within
h
surveil
sustain
financi
support
need
garner
econom
weaker
countri
moreov
dedic
advocaci
must
order
keep
topic
vaccin
prevent
viral
diseas
nation
region
intern
agenda
howev
simultan
ask
question
vaccin
everi
viral
diseasei
practic
justic
tri
find
proper
answer
vaccin
viral
diseas
feasibl
vast
divers
countri
like
india
diseas
burden
clear
mani
viral
diseas
henc
need
diseas
burden
studi
resourc
properli
util
indigen
vaccin
develop
effort
focu
viral
diseas
proven
establish
burden
diseas
mani
virus
mutat
rapidli
strain
replac
occur
everi
year
eg
season
influenza
india
afford
mimic
west
tri
introduc
season
influenza
vaccin
would
financi
impract
also
logist
nightmar
virus
like
hiv
vaccin
avail
probabl
quit
time
effort
need
focus
bring
behavior
chang
adjunct
therapeut
intervent
diseas
like
hepat
b
cheap
effect
vaccin
alreadi
avail
programmat
deadlock
broken
everi
newborn
get
vaccin
type
hepat
like
hepat
e
manag
implement
simpl
public
health
measur
handwash
improv
sanit
renew
hope
treat
hepat
c
new
potent
oral
hcvproteas
inhibitor
boceprevir
moreov
need
health
educ
activ
parent
make
inform
choic
vaccin
children
mandatori
varicella
vaccin
other
highli
expens
hpv
vaccin
lastli
unfinish
programm
like
polio
erad
complet
soon
possibl
time
second
dose
measl
vaccin
initi
kickstart
pick
momentum
time
achiev
target
set
millennium
develop
goal
